Viatris shares rise 5.01% intraday as Burney ETF buys 222K shares and analysts upgrade to Buy.

Viatris Inc. surged 5.01% intraday following a new investment by the Burney U.S. Factor Rotation ETF, which purchased 222,793 shares, signaling institutional confidence. Concurrently, analysts upgraded the stock to a "Buy" rating with a raised price target of $16, citing progress in regulatory advancements and the company’s focus on affordable medicines. These developments, despite ongoing revenue challenges, likely fueled immediate buying pressure during regular trading hours. The ETF’s entry and analyst optimism aligned with the stock’s intraday rally, reflecting renewed investor interest in Viatris’s strategic initiatives.